Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

The Eleventh ENBDC Workshop: Advances in Technology Help to Unveil Mechanisms of Mammary Gland Development and Cancerogenesis.

Vafaizadeh V, Peuhu E, Mikkola ML, Khaled WT, Bentires-Alj M, Koledova Z.

J Mammary Gland Biol Neoplasia. 2019 Sep;24(3):201-206. doi: 10.1007/s10911-019-09436-0. Epub 2019 Sep 7. Review.

PMID:
31494779
2.

Glucocorticoids promote breast cancer metastasis.

Obradović MMS, Hamelin B, Manevski N, Couto JP, Sethi A, Coissieux MM, Münst S, Okamoto R, Kohler H, Schmidt A, Bentires-Alj M.

Nature. 2019 Mar;567(7749):540-544. doi: 10.1038/s41586-019-1019-4. Epub 2019 Mar 13.

PMID:
30867597
3.

Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.

Shin MK, Payne S, Bilger A, Matkowskyj KA, Carchman E, Meyer DS, Bentires-Alj M, Deming DA, Lambert PF.

Clin Cancer Res. 2019 Mar 15;25(6):1889-1900. doi: 10.1158/1078-0432.CCR-18-2843. Epub 2018 Dec 7.

4.

European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers.

Koledova Z, Howard BA, Englund J, Bach K, Bentires-Alj M, Gonzalez-Suarez E.

Breast Cancer Res. 2018 Sep 4;20(1):102. doi: 10.1186/s13058-018-1032-9.

5.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

Raap M, Gronewold M, Christgen H, Glage S, Bentires-Alj M, Koren S, Derksen PW, Boelens M, Jonkers J, Lehmann U, Feuerhake F, Kuehnle E, Gluz O, Kates R, Nitz U, Harbeck N, Kreipe HH, Christgen M.

Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.

6.

SHP2 regulates proliferation and tumorigenicity of glioma stem cells.

Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N, O'Rourke DM.

J Neurooncol. 2017 Dec;135(3):487-496. doi: 10.1007/s11060-017-2610-x. Epub 2017 Aug 29.

PMID:
28852935
7.

The ninth ENBDC Weggis meeting: growth and in-depth characterisation of normal and neoplastic breast cells.

Wiese KE, Amante RJ, Vivanco MD, Bentires-Alj M, Iggo RD.

Breast Cancer Res. 2017 Aug 22;19(1):96. doi: 10.1186/s13058-017-0891-9.

8.

Cancer cell redirection biomarker discovery using a mutual information approach.

Roche K, Feltus FA, Park JP, Coissieux MM, Chang C, Chan VBS, Bentires-Alj M, Booth BW.

PLoS One. 2017 Jun 8;12(6):e0179265. doi: 10.1371/journal.pone.0179265. eCollection 2017.

9.

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome.

Koren S, Bentires-Alj M.

Cancer Cell. 2017 May 8;31(5):616-618. doi: 10.1016/j.ccell.2017.04.010.

10.

RNA Expression Profiling Reveals Differentially Regulated Growth Factor and Receptor Expression in Redirected Cancer Cells.

Schmucker HS, Park JP, Coissieux MM, Bentires-Alj M, Feltus FA, Booth BW.

Stem Cells Dev. 2017 May 1;26(9):646-655. doi: 10.1089/scd.2016.0340. Epub 2017 Feb 23.

PMID:
28112572
11.

The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.

Britschgi A, Duss S, Kim S, Couto JP, Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, Voshol H, Vissieres A, Leroy C, Roloff T, Stadler MB, Scheel CH, Miraglia LJ, Orth AP, Bonamy GM, Reddy VA, Bentires-Alj M.

Nature. 2017 Jan 26;541(7638):541-545. doi: 10.1038/nature20829. Epub 2017 Jan 9.

12.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

13.

Complexity galore: 3D cultures, biomechanics and systems medicine at the eighth ENBDC workshop "Methods in Mammary Gland Development and Cancer".

Lloyd-Lewis B, van de Moosdijk AA, Bentires-Alj M, Clarke RB, van Amerongen R.

Breast Cancer Res. 2016 Nov 25;18(1):115.

14.

Serpin E2 promotes breast cancer metastasis by remodeling the tumor matrix and polarizing tumor associated macrophages.

Smirnova T, Bonapace L, MacDonald G, Kondo S, Wyckoff J, Ebersbach H, Fayard B, Doelemeyer A, Coissieux MM, Heideman MR, Bentires-Alj M, Hynes NE.

Oncotarget. 2016 Dec 13;7(50):82289-82304. doi: 10.18632/oncotarget.12927.

15.

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.

Leroy C, Ramos P, Cornille K, Bonenfant D, Fritsch C, Voshol H, Bentires-Alj M.

Breast Cancer Res. 2016 Apr 5;18(1):41. doi: 10.1186/s13058-016-0697-1.

16.

Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.

Koren S, Bentires-Alj M.

Mol Cell. 2015 Nov 19;60(4):537-46. doi: 10.1016/j.molcel.2015.10.031. Review.

17.

The seventh ENBDC workshop on methods in mammary gland development and cancer.

Glukhova MA, Hynes N, Vivanco Md, van Amerongen R, Clarke RB, Bentires-Alj M.

Breast Cancer Res. 2015 Sep 2;17:119. doi: 10.1186/s13058-015-0629-5.

18.

PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.

Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T, Kohler H, Aina O, Cardiff RD, Bentires-Alj M.

Nature. 2015 Sep 3;525(7567):114-8. doi: 10.1038/nature14669. Epub 2015 Aug 12.

PMID:
26266975
19.

Stimulating translational research: several European life science institutions put their heads together.

Bentires-Alj M, Rajan A, van Harten W, van Luenen HG, Kubicek S, Andersen JB, Saarela J, Cook SJ, Van Minnebruggen G, Roman-Roman S, Maurer C, Erler JT, Bertero MG.

Trends Mol Med. 2015 Sep;21(9):525-7. doi: 10.1016/j.molmed.2015.07.002. Epub 2015 Aug 5.

PMID:
26254816
20.

CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.

Leroy C, Shen Q, Strande V, Meyer R, McLaughlin ME, Lezan E, Bentires-Alj M, Voshol H, Bonenfant D, Alex Gaither L.

Oncogene. 2015 Oct 29;34(44):5593-8. doi: 10.1038/onc.2015.19. Epub 2015 Mar 2.

21.

Breast cancer prevention: lessons to be learned from mechanisms of early pregnancy-mediated breast cancer protection.

Meier-Abt F, Bentires-Alj M, Rochlitz C.

Cancer Res. 2015 Mar 1;75(5):803-7. doi: 10.1158/0008-5472.CAN-14-2717. Epub 2015 Feb 6.

22.

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.

Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M.

Nature. 2014 Nov 6;515(7525):130-3. doi: 10.1038/nature13862. Epub 2014 Oct 22.

PMID:
25337873
23.

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Ramos P, Bentires-Alj M.

Oncogene. 2015 Jul;34(28):3617-26. doi: 10.1038/onc.2014.314. Epub 2014 Sep 29. Review.

PMID:
25263438
24.

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

Leroy C, Amante RJ, Bentires-Alj M.

Biochem Soc Trans. 2014 Aug;42(4):733-41. doi: 10.1042/BST20140034. Review.

PMID:
25109950
25.
26.

Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.

Sausgruber N, Coissieux MM, Britschgi A, Wyckoff J, Aceto N, Leroy C, Stadler MB, Voshol H, Bonenfant D, Bentires-Alj M.

Oncogene. 2015 Apr 23;34(17):2272-8. doi: 10.1038/onc.2014.170. Epub 2014 Jun 16.

PMID:
24931162
27.

Memo is a copper-dependent redox protein with an essential role in migration and metastasis.

MacDonald G, Nalvarte I, Smirnova T, Vecchi M, Aceto N, Dolemeyer A, Frei A, Lienhard S, Wyckoff J, Hess D, Seebacher J, Keusch JJ, Gut H, Salaun D, Mazzarol G, Disalvatore D, Bentires-Alj M, Di Fiore PP, Badache A, Hynes NE.

Sci Signal. 2014 Jun 10;7(329):ra56. doi: 10.1126/scisignal.2004870.

PMID:
24917593
28.

Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells.

Duss S, Brinkhaus H, Britschgi A, Cabuy E, Frey DM, Schaefer DJ, Bentires-Alj M.

Breast Cancer Res. 2014 Jun 10;16(3):R60. doi: 10.1186/bcr3673.

29.

MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.

Shostak K, Patrascu F, Göktuna SI, Close P, Borgs L, Nguyen L, Olivier F, Rammal A, Brinkhaus H, Bentires-Alj M, Marine JC, Chariot A.

Cell Death Differ. 2014 May;21(5):811-24. doi: 10.1038/cdd.2014.2. Epub 2014 Jan 31.

30.

VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation.

Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U, Bentires-Alj M, Christofori G.

Cancer Res. 2014 Mar 1;74(5):1566-75. doi: 10.1158/0008-5472.CAN-13-1641. Epub 2014 Jan 10.

31.

How pregnancy at early age protects against breast cancer.

Meier-Abt F, Bentires-Alj M.

Trends Mol Med. 2014 Mar;20(3):143-53. doi: 10.1016/j.molmed.2013.11.002. Epub 2013 Dec 16. Review.

PMID:
24355762
32.

Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?

Britschgi A, Radimerski T, Bentires-Alj M.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):68-72. doi: 10.1016/j.drup.2013.10.001. Epub 2013 Oct 10. Review.

PMID:
24169539
34.

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.

Meyer DS, Koren S, Leroy C, Brinkhaus H, Müller U, Klebba I, Müller M, Cardiff RD, Bentires-Alj M.

Oncogenesis. 2013 Sep 30;2:e74. doi: 10.1038/oncsis.2013.38.

35.

Mammary tumor formation and metastasis evoked by a HER2 splice variant.

Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M.

Cancer Res. 2013 Sep 1;73(17):5320-7. doi: 10.1158/0008-5472.CAN-12-3186. Epub 2013 Jul 18.

36.

A tumorigenic actin mutant alters fibroblast morphology and multicellular assembly properties.

Blache U, Silván U, Plodinec M, Suetterlin R, Jakob R, Klebba I, Bentires-Alj M, Aebi U, Schoenenberger CA.

Cytoskeleton (Hoboken). 2013 Oct;70(10):635-50. doi: 10.1002/cm.21120. Epub 2013 Jul 19.

PMID:
23804571
37.

Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium.

Meier-Abt F, Milani E, Roloff T, Brinkhaus H, Duss S, Meyer DS, Klebba I, Balwierz PJ, van Nimwegen E, Bentires-Alj M.

Breast Cancer Res. 2013 Apr 29;15(2):R36. doi: 10.1186/bcr3419.

38.

Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.

Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy CT, Wetzel K, George E, Popa MO, Lilley S, Choudhury H, Gosling M, Wang L, Fitzgerald S, Borawski J, Baffoe J, Labow M, Gaither LA, Bentires-Alj M.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):E1026-34. doi: 10.1073/pnas.1217072110. Epub 2013 Feb 19.

39.

Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.

Koren S, Bentires-Alj M.

FEBS J. 2013 Jun;280(12):2758-65. doi: 10.1111/febs.12175. Epub 2013 Mar 1. Review.

40.

Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.

Meyer DS, Aceto N, Sausgruber N, Brinkhaus H, Müller U, Pallen CJ, Bentires-Alj M.

Oncogene. 2014 Jan 16;33(3):398-402. doi: 10.1038/onc.2012.585. Epub 2013 Jan 14.

PMID:
23318421
41.

JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.

Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Müller U, Murakami M, Radimerski T, Bentires-Alj M.

Cancer Cell. 2012 Dec 11;22(6):796-811. doi: 10.1016/j.ccr.2012.10.023.

42.

Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation.

Milani ES, Brinkhaus H, Dueggeli R, Klebba I, Mueller U, Stadler M, Kohler H, Smalley MJ, Bentires-Alj M.

Development. 2013 Jan 1;140(1):117-25. doi: 10.1242/dev.082941. Epub 2012 Nov 15.

43.

The nanomechanical signature of breast cancer.

Plodinec M, Loparic M, Monnier CA, Obermann EC, Zanetti-Dallenbach R, Oertle P, Hyotyla JT, Aebi U, Bentires-Alj M, Lim RY, Schoenenberger CA.

Nat Nanotechnol. 2012 Nov;7(11):757-65. doi: 10.1038/nnano.2012.167. Epub 2012 Oct 21.

PMID:
23085644
44.

Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion.

Aceto N, Duss S, MacDonald G, Meyer DS, Roloff TC, Hynes NE, Bentires-Alj M.

Breast Cancer Res. 2012 Oct 12;14(5):R131. doi: 10.1186/bcr3329.

45.

K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.

Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM.

PLoS One. 2012;7(8):e44146. doi: 10.1371/journal.pone.0044146. Epub 2012 Aug 31.

46.

Hippo inactivation feeds tumor-initiating cells.

Duss S, Britschgi A, Bentires-Alj M.

Breast Cancer Res. 2012 Aug 7;14(4):318. doi: 10.1186/bcr3190.

47.

New methods in mammary gland development and cancer: proteomics, epigenetics, symmetric division and metastasis.

Bentires-Alj M, Glukhova M, Hynes N, Vivanco M.

Breast Cancer Res. 2012 Jul 19;14(4):314. doi: 10.1186/bcr3216.

48.

Critical questions in mammary gland development, lactational biology and breast cancer.

Bentires-Alj M, Wood TL.

J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):89-90. doi: 10.1007/s10911-012-9260-6. No abstract available.

PMID:
22729429
49.

Targeting protein-tyrosine phosphatases in breast cancer.

Aceto N, Bentires-Alj M.

Oncotarget. 2012 May;3(5):514-5.

50.

On the road to combinations of targeted therapies: PPM1H phosphatase as a suppressor of trastuzumab resistance.

Aceto N, Bentires-Alj M.

Cancer Discov. 2011 Sep;1(4):285-6. doi: 10.1158/2159-8290.CD-11-0185.

Supplemental Content

Loading ...
Support Center